CrownBio's Integrated Oncology Platform Helps Advance Apogenix's Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer
(Thomson Reuters ONE) -
SANTA CLARA, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a
wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and
a global drug discovery and development services company providing translational
platforms to advance oncology, inflammation, cardiovascular and metabolic
disease research, announces that their integrated oncology platform has
facilitated the preclinical development of a HERA-GITRL immunotherapeutic from
Apogenix. HERA-GITRL is an immunotherapy showing antitumor activity in Non-Small
Cell Lung Cancer (NSCLC) and Head and Neck Cancer.
The data derived from studies using CrownBio's portfolio were first presented by
Apogenix in an oral presentation at the AACR 2017 Annual Meeting. These data
showed the immunotherapy's potential clinical utility and demonstrated the
benefits of using CrownBio's platform in preclinical efficacy testing.
"CrownBio's integrated oncology platform confirmed our agent's efficacy in NSCLC
and head and neck cancers," said Dr. Mauricio Redondo Müller, Director,
Preclinical Development at Apogenix. "The scientific expertise, predictive
tools, and well-validated models CrownBio provides gave us the data we needed to
progress our HERA-GITRL immunotherapy to the next stage."
"It is our mission to deliver innovative technologies so that companies like
Apogenix can leverage and accelerate their research," said Laurie Heilmann, SVP
of Global Strategy, Marketing & Business Development. "Our scientific oncology
platform uniquely enhances preclinical immunotherapy development and will
continue to deliver valuable insights that drive new discoveries in this area."
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company
providing translational platforms to advance oncology, inflammation,
cardiovascular and metabolic disease research. With an extensive portfolio of
relevant models and predictive tools, Crown Bioscience enables clients to
deliver superior clinical candidates.
About Apogenix
Apogenix develops innovative immuno-oncology therapeutics for the treatment of
cancer and other malignant diseases. The company has built a promising pipeline
of immuno-oncology drug candidates that target different tumor necrosis factor
superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune
response against tumors. Since its inception in fall 2005, Apogenix has raised
more than 100 million euros in financing rounds, public grants, and upfront
payments from licensing agreements. The company is based in Heidelberg, Germany.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. marketing(at)crownbio.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via GlobeNewswire
Datum: 13.09.2017 - 16:28 Uhr
Sprache: Deutsch
News-ID 559829
Anzahl Zeichen: 3483
contact information:
Town:
Santa Clara
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 282 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CrownBio's Integrated Oncology Platform Helps Advance Apogenix's Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Crown Bioscience Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
